Global Impotence Agents Market – Industry Trends and Forecast to 2029

Impotence Agents Market Analysis and Size

The global impotence agents market is expected to witness significant growth during the forecast period. Many reasons that can cause erectile dysfunction such as atherosclerosis, hypertension, diabetes, obesity, depression, stress and other medical conditions will also boost the global impotence agents market. side effects after the administration of impotence agents may hamper the impotence agent market. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global impotence agents market in the forecast period 2022-2029. The expected CAGR of global impotence agents market is tend to be around 7% in the mentioned forecast period. The market was valued at USD 3.6 billion in 2021, and it would grow upto USD 6.19 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Impotence agents are the type of agents that used to treat erectile dysfunction in males and enable to increase sexual intercourse. These agents generally increase vasodilation and blood flow to the male genital organ and cause an erection.  It is becoming of great importance to the healthcare sector and is expected to expand in the coming times.

Impotence Agents Market Scope and Segmentation

Global Impotence Agents Market Dynamics

Drivers

• Increased Incidence of Erectile Dysfunction

Increasing prevalence of erectile dysfunction are expected to boost the market growth over the forecast period 2022-2029. For instance, according to the World Health Organization (WHO) reports, approximately 150 million people are affected by erectile dysfunction globally, and the number is expected to reach 230 million by 2025. Erectile Dysfunction is a  common medical condition affecting about 15% of men annually. Thus, it boosts market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to prompt the market growth. The segment is expected to boost the global market as most products are available in capsule and tablet form and it is a very suitable route of administration.

Opportunities

• Increasing Demand for Retail Pharmacies

The rise in the number of impotence agents delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Risk of Side-Effects

The varied side-effects associated with impotence agents could curb the growth of the global PDE inhibitors market over a forecast period. Side-effects such as dyspepsia and headache, and to a lesser extent, myalgia, low-back pain, flushing, and rhinitis are visible with the use of impotence agents.

• High Cost

The huge expenditure associated with these agents surely hamper the market growth.

This global impotence agents market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global impotence agents market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Impotence Agents Market            

COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term consequences are expected to boost the industry growth during the forecast period. The shift of healthcare infrastructure towards managing COVID-19 has led to drug launch cancellations and delays in clinical trials.

In the post-pandemic era, changes are witnessed in use of different inhibitors. Socioeconomic stressors have also increased the demand for these drugs. Thus, this will leave a significant impact on the global impotence agents market.

Global Impotence Agents Market Scope

The global impotence agents market is segmented on the basis of product, indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Erectile Dysfunction
• Others

Product

• Tablets
• Injections
• Urethral Suppository
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Impotence Agents Market Regional Analysis/Insights

The global impotence agents market is analysed and market size insights and trends are provided by product, indication, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global impotence agents market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global impotence agents market throughout the forecasted period due to increasing hypertension and diabetes patients and increased prevalence of erectile dysfunction in males.

North America dominates the market due to increasing initiatives taken by the pharmaceutical organizations to generate novel formulations.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Impotence Agents Market Share Analysis

The global impotence agents market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global impotence agents market

Key players operating in the global impotence agents market include:

• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Hikma Pharmaceuticals plc (U.K.)
• Aurobindo Pharma (India)
• Abbvie Inc (U.S.)
• Melinta Therapeutics, llc (U.S.)
• Janssen Global Services, LLC (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• Lilly (U.S.)
• AstraZeneca (India)

SKU-54079